Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK) AI-Powered Stock Analysis
See how Hanx Biopharmaceuticals (Wuhan) Co., Ltd. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
3378.HK●HKSE
HealthcareBiotechnology
HK$25.84
HK$1.72(6.24%)
Hong Kong Market is Open · 15:48
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerHanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK) Stock Overall Grade
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Hanx Biopharmaceuticals (Wuhan) Co., Ltd.'s overall stock rating.
Forecast
AScore
89/100Financial Growth
CScore
40/100Fundamental Growth
BScore
65/100Key Ratios
BScore
67/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 89/100 (A), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (65/100, B) highlight its stability, while Key Ratios (67/100, B) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Hanx Biopharmaceuticals (Wuhan) Co., Ltd. stock grade, including financials, comparisons, and forecasts.